RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Daito Pharmaceutical Co - Stock

Daito Pharmaceutical Co Net Income 2024

Daito Pharmaceutical Co Net Income

3.04 B JPY

Ticker

4577.T

ISIN

JP3486150000

WKN

A1CXXT

In 2024, Daito Pharmaceutical Co's profit amounted to 3.04 B JPY, a -15.56% increase from the 3.6 B JPY profit recorded in the previous year.

The Daito Pharmaceutical Co Net Income history

YEARNET INCOME (undefined JPY)
2027e6.37
2026e4.45
2025e3.89
2024e3.04
20233.6
20224.67
20214.25
20203.94
20193.51
20183.04
20172.66
20162.57
20152.25
20141.81
20131.79
20121.39
20110.99
20100.75
20090.69
20080.75
20070.71
20060.47
2005-0.63

Daito Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Daito Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Daito Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Daito Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Daito Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Daito Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Daito Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Daito Pharmaceutical Co’s growth potential.

Daito Pharmaceutical Co Revenue, EBIT and net profit per share

DateDaito Pharmaceutical Co RevenueDaito Pharmaceutical Co EBITDaito Pharmaceutical Co Net Income
2027e55.97 B JPY0 JPY6.37 B JPY
2026e56.36 B JPY0 JPY4.45 B JPY
2025e52.52 B JPY0 JPY3.89 B JPY
2024e47.37 B JPY0 JPY3.04 B JPY
202345.1 B JPY5.21 B JPY3.6 B JPY
202243.46 B JPY6.55 B JPY4.67 B JPY
202148.71 B JPY5.91 B JPY4.25 B JPY
202044.99 B JPY5.36 B JPY3.94 B JPY
201941.13 B JPY4.55 B JPY3.51 B JPY
201839.88 B JPY4.16 B JPY3.04 B JPY
201737.98 B JPY3.83 B JPY2.66 B JPY
201636.37 B JPY3.56 B JPY2.57 B JPY
201534.06 B JPY3.52 B JPY2.25 B JPY
201431.2 B JPY2.94 B JPY1.81 B JPY
201328.96 B JPY2.68 B JPY1.79 B JPY
201227.15 B JPY2.63 B JPY1.39 B JPY
201125.23 B JPY1.96 B JPY991 M JPY
201022.68 B JPY1.45 B JPY752 M JPY
200921.52 B JPY1.34 B JPY693 M JPY
200820.76 B JPY1.79 B JPY752 M JPY
200716.99 B JPY1.24 B JPY705 M JPY
200615.54 B JPY1.07 B JPY472 M JPY
200514.17 B JPY1.07 B JPY-632 M JPY

Daito Pharmaceutical Co stock margins

The Daito Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Daito Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Daito Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Daito Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Daito Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Daito Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Daito Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Daito Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Daito Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Daito Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Daito Pharmaceutical Co Margin History

Daito Pharmaceutical Co Gross marginDaito Pharmaceutical Co Profit marginDaito Pharmaceutical Co EBIT marginDaito Pharmaceutical Co Profit margin
2027e22.91 %0 %11.38 %
2026e22.91 %0 %7.9 %
2025e22.91 %0 %7.4 %
2024e22.91 %0 %6.42 %
202322.91 %11.55 %7.98 %
202226.36 %15.08 %10.74 %
202122.17 %12.13 %8.72 %
202021.07 %11.91 %8.77 %
201921.08 %11.05 %8.54 %
201820.34 %10.44 %7.63 %
201720.41 %10.09 %6.99 %
201619.98 %9.78 %7.06 %
201520.75 %10.33 %6.59 %
201419.18 %9.42 %5.81 %
201320.46 %9.26 %6.17 %
201220.85 %9.68 %5.12 %
201118.66 %7.77 %3.93 %
201016.29 %6.41 %3.32 %
200916.66 %6.24 %3.22 %
200818.19 %8.64 %3.62 %
200717.17 %7.31 %4.15 %
200617.04 %6.88 %3.04 %
200517.17 %7.52 %-4.46 %

Daito Pharmaceutical Co Aktienanalyse

What does Daito Pharmaceutical Co do?

Daito Pharmaceutical Co Ltd is a Japanese pharmaceutical company that was founded in 1947. The company is headquartered in Osaka and is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Daito Pharmaceutical specializes in the development and manufacturing of medications and has a strong presence in the East Asia region. History: Daito Pharmaceutical was founded by Masaharu Imai, a pharmacist driven by the idea of producing medications that would help people and alleviate suffering. The company started as a small family business, producing a limited number of medications in a workshop in Osaka. Some of the earliest products were injection solutions and ready-to-use medications. In the 1950s, Daito Pharmaceutical expanded its product range and began developing medications for chronic diseases such as diabetes and heart diseases. The company also expanded geographically and started selling its products in other parts of Japan. In the following years, Daito Pharmaceutical expanded its capabilities and presence through mergers and acquisitions. One of the most significant acquisitions was the acquisition of Union Chemical Industry Co Ltd in 1973. This acquisition expanded Daito Pharmaceutical's portfolio with new products and technologies, as well as customers and distribution channels in other countries. Business model: Daito Pharmaceutical is a company that focuses on the development, manufacturing, and marketing of prescription and OTC medications. The company is divided into several business units that specialize in specific therapeutic areas. One of Daito Pharmaceutical's largest business units is the oncology division. Here, the company works on developing new cancer medications and supports doctors in the treatment of patients with cancer. Another business unit is the neurology division, which focuses on the development of medications for the treatment of neurological disorders such as Alzheimer's and Parkinson's. Products: Daito Pharmaceutical offers a wide range of medications that can be used for a variety of conditions. The company's products are divided into various therapy areas, including cardiology, oncology, neurology, and gastroenterology. An example of a Daito Pharmaceutical product is Nazastat (Nafazaon), a medication used for the treatment of type 2 diabetes. It is administered orally and works by inhibiting glucose production in the liver and improving insulin sensitivity in muscle and fat tissues. Another product of Daito Pharmaceutical is Tegosept (Methisazin), a medication used for the treatment of upper respiratory tract infections such as sinusitis and pharyngitis. The medication is administered orally and works by inhibiting the growth of bacteria such as Streptococcus and Staphylococcus. Conclusion: Daito Pharmaceutical Co Ltd is a Japanese pharmaceutical company that specializes in the development, manufacturing, and marketing of medications. The company has a long history in the industry and has expanded its capabilities and presence over the years through mergers and acquisitions. Daito Pharmaceutical has several business units specializing in different therapeutic areas, including oncology, neurology, and cardiology. The company offers a wide range of medications that can be used for a variety of conditions. Daito Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Daito Pharmaceutical Co's Profit Margins

The profit margins of Daito Pharmaceutical Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Daito Pharmaceutical Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Daito Pharmaceutical Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Daito Pharmaceutical Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Daito Pharmaceutical Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Daito Pharmaceutical Co Stock

How much profit has Daito Pharmaceutical Co made this year?

Daito Pharmaceutical Co has made 3.04 B JPY this year.

How has the profit developed compared to last year?

The profit has increased by -15.56% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Daito Pharmaceutical Co publish its earnings?

Daito Pharmaceutical Co publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Daito Pharmaceutical Co?

The profits of Daito Pharmaceutical Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Daito Pharmaceutical Co?

You can learn more about the earnings of Daito Pharmaceutical Co by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Daito Pharmaceutical Co pay?

Over the past 12 months, Daito Pharmaceutical Co paid a dividend of 60 JPY . This corresponds to a dividend yield of about 2.69 %. For the coming 12 months, Daito Pharmaceutical Co is expected to pay a dividend of 65.13 JPY.

What is the dividend yield of Daito Pharmaceutical Co?

The current dividend yield of Daito Pharmaceutical Co is 2.69 %.

When does Daito Pharmaceutical Co pay dividends?

Daito Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of December, June, December, June.

How secure is the dividend of Daito Pharmaceutical Co?

Daito Pharmaceutical Co paid dividends every year for the past 18 years.

What is the dividend of Daito Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 65.13 JPY are expected. This corresponds to a dividend yield of 2.92 %.

In which sector is Daito Pharmaceutical Co located?

Daito Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Daito Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Daito Pharmaceutical Co from 8/1/2024 amounting to 30 JPY, you needed to have the stock in your portfolio before the ex-date on 5/30/2024.

When did Daito Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of Daito Pharmaceutical Co in the year 2023?

In the year 2023, Daito Pharmaceutical Co distributed 39.091 JPY as dividends.

In which currency does Daito Pharmaceutical Co pay out the dividend?

The dividends of Daito Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Daito Pharmaceutical Co

Our stock analysis for Daito Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Daito Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.